Answers are grounded in this paper and cite their sources.
Novel redox-responsive cross-linked PAMAM dendrimers enhance gene delivery in cancer cells, suggesting new theranostic applications.
This work presents a novel strategy for enhancing the gene delivery capabilities of low-generation poly(amidoamine) (PAMAM) dendrimers by employing a fluorinated, redox-responsive cross-linker. The synthesized cross-linker, featuring both disulfide bonds and trifluoromethyl groups, facilitates efficient "click" Michael addition with PAMAM G2, producing cross-linked polymers with strong 19F nuclear magnetic resonance signals and favorable relaxation properties, enabling their use as 19F nuclear magnetic resonance tracers. The resulting fluorinated PAMAM G2 polymers also demonstrated excellent plasmid DNA complexation, glutathione-triggered degradation, and notably enhanced transfection efficiency, especially in cancerous HeLa cells notoriously associated with a reducing environment, while maintaining low cytotoxicity. The best-performing system, derived from PAMAM G2 reacted with the redox-responsive cross-linker in a 1:1 molar ratio, outperformed both unmodified PAMAM G2 and 25 kDa branched polyethylenimine, the current nonviral transfection gold standard. These findings highlight the potential of fluorinated bioreducible dendrimer networks as multifunctional, low-toxicity, and trackable platforms for efficient gene delivery and theranostic applications.
No takes yet. Share an insight, caveat, or question.
Romani et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: